Pazopanib 200 Cipla 200 mg Tablet
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced and/or metastatic renal cell carcinoma.
Dosage (summary)
800 mg orally once daily; modify in 200 mg increments based on tolerability.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly population
Pregnancy & Breastfeeding
Not recommended during pregnancy; potential reproductive toxicity. Breastfeeding not established.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Simvastatin
- Grapefruit juice
Contraindications
- Hypersensitivity to pazopanib or excipients
Common side effects
- Diarrhoea
- Hypertension
- Nausea
- Fatigue
- Elevated liver enzymes
Counselling Points
- Take on an empty stomach.
- Monitor liver function regularly.
- Use contraception during treatment.
- Report any signs of bleeding or severe hypertension.
Serious warnings
- Cerebrovascular adverse events
- Hepatic failure
- Hypertension
- QT prolongation
- Cardiac dysfunction
Important Disclaimer
The Pazopanib 200 Cipla 200 mg Tablet professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
